Recalls & Warnings December 08, 2017 Limbrel Capsules for Osteoarthritis Linked With Potentially Life-Threatening Health Risk, FDA Warns On December 4, 2017, the FDA urged consumers not to take Limbrel (Primus Pharmaceuticals), a capsule marketed to manage the metabolic processes associated with osteoarthritis, because it has been associated with serious adverse events, including drug-induced liver injury and a lung
This integration exemplifies process analytical technology (PAT) and quality by design (QbD) principles, preventing batch deviations and ensuring consistent product quality from the outset [499, 500]
We use Advanced Medical Testing insights to make IV therapies that fit your health needs
Considering the notion has been raised that sub-clinical presentation of konzo exists, these measures may allow for the identification of individuals who show similar reduced antioxidant capacity as those with konzo, but who do not show a visible physical disability, enabling the overdue refinement of the clinical features associated with this disease 3,42